A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors UCB Biopharma
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2017 This trial has been discontinued in Germany.